|
Researchers from Harvard’s Kennedy School and Brown’s School of Public Health penned an op-ed praising the CMS drug price negotiation program while also asserting that it needs to move faster and include more treatments. They also mention the role of ICER in the US health care system:
“The Food and Drug Administration asks whether a drug is safe and effective. It does not ask whether a $200,000-a-year drug is worth $200,000 a year.
Many wealthy nations have some version of that question built into their systems, including the US. It has the Institute for Clinical and Economic Review, or ICER, an independent, privately funded agency that rigorously analyzes whether drug prices are justified by clinical benefit. Its work is credible and widely respected. It is also entirely advisory. No payer is required to consider it. Giving ICER’s analyses real weight in Medicare’s negotiating positions — not as a trigger for coverage denials, but as an anchor for what we are willing to pay — would help close the gap between what drugs cost and what they do for patients.
Expanding negotiation, fixing the patent system, and requiring that price reflect value at launch would not eliminate pharmaceutical innovation — they would redirect it toward the patients it is supposed to serve.”
|